QQQ $ 617.80 $ 0.00 (0 %)
DIA $ 470.95 $ 0.00 (0 %)
SPY $ 674.37 $ 0.00 (0 %)
TLT $ 89.95 $ 0.00 (0 %)
GLD $ 364.75 $ 0.00 (0 %)
$ 0.3291
-- x --
-- x --
-- - --
$ 0.22 - $ 1.56
725,841
na
29.74M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2025 03-31-2025 10-Q
2 03-12-2025 12-31-2024 10-K
3 11-06-2024 09-30-2024 10-Q
4 08-07-2024 06-30-2024 10-Q
5 05-09-2024 03-31-2024 10-Q
6 03-14-2024 12-31-2023 10-K
7 11-13-2023 09-30-2023 10-Q
8 08-09-2023 06-30-2023 10-Q
9 05-09-2023 03-31-2023 10-Q
10 03-06-2023 12-31-2022 10-K
11 11-07-2022 09-30-2022 10-Q
12 08-04-2022 06-30-2022 10-Q
13 05-06-2022 03-31-2022 10-Q
14 03-01-2022 12-31-2021 10-K
15 11-08-2021 09-30-2021 10-Q
16 08-09-2021 06-30-2021 10-Q
17 05-10-2021 03-31-2021 10-Q
18 03-01-2021 12-31-2020 10-K
19 11-09-2020 09-30-2020 10-Q
20 08-10-2020 06-30-2020 10-Q
21 05-11-2020 03-31-2020 10-Q
22 02-25-2020 12-31-2019 10-K
23 11-12-2019 09-30-2019 10-Q
24 08-05-2019 06-30-2019 10-Q
25 05-08-2019 03-31-2019 10-Q
26 03-14-2019 12-31-2018 10-K
27 11-08-2018 09-30-2018 10-Q
28 08-29-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 allakos-enters-agreement-to-be-acquired-by-concentra-biosciences-for-033-in-cash-per-share-merger-expected-to-close-in-may-2025

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company ...

 deal-dispatch-sage-and-silvus-are-up-for-sale-mrbeast-secures-20b-for-tiktok

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

 why-is-allakos-stock-plunging-on-monday

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 mill...

 allakos-announced-topline-results-from-its-phase-1-clinical-trial-of-ak006-in-chronic-spontaneous-urticaria-ak006-did-not-demonstrate-therapeutic-activity-allakos-will-discontinue-further-development-of-ak006-reduce-workforce-by-75-and-explore-strategic-alternatives

Phase 1 Cohort of AK006 in Patients with Chronic Spontaneous UrticariaIn the CSU cohort, 34 adult patients with moderate-to-sev...

 allakos-announces-phase-1-trial-results-of-subcutaneous-ak006-in-healthy-volunteers-subcutaneously-administered-ak006-showed-77-bioavailability-and-prolonged-receptor-occupancy-on-mast-cells-was-well-tolerated-with-a-favorable-safety-profile

– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– ...

 jmp-securities-reiterates-market-outperform-on-allakos-maintains-3-price-target

JMP Securities analyst Jonathan Wolleben reiterates Allakos (NASDAQ:ALLK) with a Market Outperform and maintains $3 price ta...

 allakos-q2-eps-030-beats-034-estimate

Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION